Create Free Account

By creating account you will get access to hot stocks & personalised emails

Paradigm Biopharmaceuticals Ltd

Healthcare AU PAR

0.365AUD
-0.01(2.67%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.360.40
LowHigh

52 Week Range

0.170.61
LowHigh

Fundamentals

  • Previous Close 0.38
  • Market Cap139.77M
  • Volume1191173
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-64.96545M
  • Revenue TTM0.04M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.03M
  • Diluted EPS TTM-0.2

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -51.91001M -39.24958M -34.29718M -12.29889M -15.62754M
Minority interest - - - - -
Net income -51.91001M -39.27822M -43.04688M -16.03090M -26.23154M
Selling general administrative 6.56M 7.93M 8.75M 4.17M 4.05M
Selling and marketing expenses - - - - -
Gross profit 0.03M -0.06453M -0.07859M - 2.98M
Reconciled depreciation - 0.06M 0.21M 0.08M 0.00835M
Ebit -60.03851M -39.22095M -34.25946M -12.26472M -5.02355M
Ebitda -51.89360M -39.15998M -34.04940M -12.05160M -5.01520M
Depreciation and amortization - 0.06M 0.21M 0.21M 0.00835M
Non operating income net other - - - - -
Operating income -51.89360M -39.22095M -34.25946M -12.26472M -5.02355M
Other operating expenses 60.09M 48.07M 43.41M 17.17M 11.95M
Interest expense 0.02M 0.03M 0.04M 0.03M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.41M 0.05M 0.04M 0.03M 0.26M
Net interest income 1.39M 0.02M 0.17M -0.03417M 0.26M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.03M 8.75M 3.73M 10.60M
Total revenue 0.05M 0.08M 0.02M 4.70M 3.25M
Total operating expenses 60.07M 47.93M 43.31M 17.17M 11.95M
Cost of revenue 0.02M 0.14M 0.10M - -
Total other income expense net 6.74M -0.02863M -0.03772M -0.03417M -10.60399M
Discontinued operations - - - - -
Net income from continuing ops -51.91001M -39.24958M -34.29718M -12.29889M -15.62754M
Net income applicable to common shares -51.91001M -39.24958M -34.29718M -12.29889M -15.62754M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 27.39M 67.07M 50.69M 84.79M 112.36M
Intangible assets - 2.95M 2.95M 2.95M 2.95M
Earning assets - - - - -
Other current assets 1.30M - 0.78M 1.43M 0.94M
Total liab 3.58M 13.39M 8.38M 6.52M 4.18M
Total stockholder equity 23.81M 53.68M 42.31M 78.27M 108.18M
Deferred long term liab - - - - -
Other current liab 0.42M 0.78M 0.59M 0.67M 0.49M
Common stock 238.11M 209.83M 147.19M 146.99M 145.87M
Capital stock - 209.83M 147.19M 146.99M 145.87M
Retained earnings -220.73014M -163.51401M -114.01554M -75.22823M -41.26855M
Other liab - 0.11M 0.08M 0.11M 0.07M
Good will - - - - -
Other assets 0.00000M - 0.00000M 0.10M 0.10M
Cash 17.82M 56.33M 39.67M 71.03M 103.92M
Cash and equivalents - - - - -
Total current liabilities 3.36M 13.04M 7.83M 5.79M 3.36M
Current deferred revenue - - - - -
Net debt -17.58150M -55.99142M -39.05774M -70.28314M -103.04855M
Short term debt 0.12M 0.10M 0.15M 0.13M 0.12M
Short long term debt - - - - -
Short long term debt total 0.24M 0.34M 0.62M 0.75M 0.87M
Other stockholder equity - -0.42878M 9.13M 6.51M 3.59M
Property plant equipment - 0.34M 0.57M 0.76M 0.94M
Total current assets 24.25M 63.79M 47.17M 80.98M 108.37M
Long term investments - - - 0.10M 0.10M
Net tangible assets - 50.73M 39.37M 75.33M 105.23M
Short term investments 0.05M 0.05M 0.05M 0.05M 0.75M
Net receivables 5.08M 6.81M 6.72M 8.51M 3.51M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.82M 12.16M 7.09M 4.99M 2.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 6.42M 7.36M 9.13M 6.51M 3.59M
Additional paid in capital - - - - -
Common stock total equity - - - - 145.87M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.95M - - - -
Deferred long term asset charges - - - - -
Non current assets total 3.14M 3.28M 3.52M 3.81M 3.99M
Capital lease obligations - 0.34M 0.62M 0.75M 0.87M
Long term debt total - 0.14M 0.37M 0.62M 0.75M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments - - 0.70M 5.75M -6.50000M
Change to liabilities 5.07M 2.10M 2.20M 0.75M 1.13M
Total cashflows from investing activities 0.00000M 0.00000M 0.67M 5.62M -6.52198M
Net borrowings -0.10449M -0.13517M -0.12185M 1.80M 1.80M
Total cash from financing activities 62.53M 0.07M 1.00M 36.05M 82.78M
Change to operating activities -0.10277M 0.54M -0.88882M -0.05527M -0.04514M
Net income -51.91001M -39.27822M -34.33491M -12.33305M -26.23154M
Change in cash 16.66M -31.36057M -32.88726M 31.59M 69.89M
Begin period cash flow 39.67M 71.03M 103.92M 72.34M 2.45M
End period cash flow 56.33M 39.67M 71.03M 103.92M 72.34M
Total cash from operating activities -45.18628M -39.21725M -34.92948M -10.09006M -6.36510M
Issuance of capital stock 65.99M - 1.02M 36.84M 88.05M
Depreciation 0.15M 0.06M 0.21M 0.21M 0.00835M
Other cashflows from investing activities 0.00000M 0.00000M 0.70M 5.75M -6.50000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.36M 1.79M -5.04870M 0.02M -0.79745M
Sale purchase of stock -3.76487M 0.00000M 1.02M -2.58845M -5.26972M
Other cashflows from financing activities 0.31M 0.07M -0.01817M 1.80M -6.52198M
Change to netincome 1.24M 2.41M 2.89M 1.28M 8.97M
Capital expenditures 0.00000M 0.00000M 0.03M 0.13M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.95M 0.05M 0.26M 1.12M 0.09M
Stock based compensation - - - - -
Other non cash items - 39.22M 34.09M 12.22M 15.62M
Free cash flow -45.18628M -39.21725M -34.96112M -0.13089M -0.02198M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PAR
Paradigm Biopharmaceuticals Ltd		 -0.01 2.67% 0.36 - - 1872.02 6.17 1963.20 -6.7826
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Paradigm Biopharmaceuticals Ltd

500 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC Founder, MD & Exec. Chairman 1959
Dr. Donna L. Skerrett M.D., MS Chief Medical Officer and Exec. Director 1957
Mr. Justin Cahill Chief Financial Officer NA
Dr. Ravi Krishnan Chief Scientific Officer NA
Mr. Simon White Director of Investor Relations NA
Dr. Michael Imperiale Global Head of Drug Safety & MPS NA
Ms. Beverley Huttmann Commercial Head NA
Ms. Michelle Coffey Global Head of Regulatory Affairs NA
Dr. Mukesh Ahuja Global Clinical Head of OA NA
Mr. Marco Polizzi Exec. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.